Immune deficiency
The immune deficiency in Wiskott-Aldrich syndrome takes various forms, but in severe cases both humoral and cell mediated immunity are impaired. Abnormalities of serum immunoglobulins with increased IgA and IgE and depressed IgM are characteristic and transient paraproteinaemias are occasionally observed. 34 Affected males commonly fail to respond to challenge with polysaccharide antigens and in many cases the B cell dysfunction leads to a pronounced susceptibility to severe infections with encapsulated organisms including Pneumococcus, Staphylococcus, and Haemophilus.5 This is manifest clinically by recurrent otitis media, skin abscesses, and sinusitis with intervening episodes of potentially fulminant pneumonia, meningitis, and septicaemia. Even in patients with attenuated variants of the syndrome, and few infective complications, polysaccharide isoagglutinins may be absent or reduced in titre and this can be a useful diagnostic marker. 6 Abnormalities of cell mediated immunity tend to Malignancy Susceptibility to malignancy is well documented in patients with Wiskott-Aldrich syndrome, and in a large series reported in 1980 by Perry and coworkers2 a cumulative annual risk of 2% was calculated with an overall 120-fold excess risk compared with the normal population. Most cases were of non-Hodgkin's lymphoma and extranodal presentation in the brain and gastrointestinal tract was particularly common. Perhaps surprisingly, acute myeloid leukaemia was seen in a significant proportion of the remaining cases. The development of malignancy in Wiskott-Aldrich syndrome is generally thought to be associated with decreased immune surveillance and is confined to those patients with clinically important immune deficiency. With recent therapeutic advances and improved survival, it might be anticipated that a greater proportion ofpatients with this complication will be encountered in the future. Peacocke" reported close linkage between the Wiskott-Aldrich syndrome gene and two loci, DXS14 and DXS7, which map to the proximal short arm of the X chromosome (p.1 1 .3-cen).
Renal disease Glomerulonephritis has recently been recognised as a relatively common complication in
Later studies indicated that the gene is flanked by these markers and comprehensive linkage data have now been reported with a cluster of pericentromeric polymorphic markers including the closely linked hypervariable locus DXS255 and the multiallelic alpha satellite sequences identified by the probe pBamX-7 at the X centromere.'2" Although the precise order of these loci in relation to the WiskottAldrich syndrome gene has yet to be established, the availability of these highly inform-ative markers now allows DNA analysis to be used for carrier detection and early prenatal diagnosis in virtually all families who segregate for the disorder.
Segregation analysis using linked probes is not possible in families in which DNA from affected males is unavailable or in which only a single male is affected. An alternative stategy to identify female carriers of Wiskott-Aldrich syndrome may, however, be used. This entails analysis of the methylation patterns of Xlinked genes in their lymphoid and haemopoietic cells to determine active and inactive chromosomes.'35 Selective suppression of precursor cells carrying active X chromosomes with the mutant Wiskott-Aldrich syndrome gene can then be identified. Probes for the genes hypoxanthine phosphoribosyl transferase and phosphoglycerate kinase are commonly used which detect restriction fragment length polymorphisms after an initial endonuclease digestion. In heterozygous females in whom maternal and paternal alleles are identified a second digestion with a methylation sensitive endonuclease-for example, HpaII-distinguishes active loci which are cut and inactive loci which are not. It is important in such cases to confirm that the skewed X-inactivation pattern is confined to the cells expressing the defect because a small proportion of normal females (about 5°%) show, by chance, an unbalanced distribution. The highly informative locus DXS255 may also be of value in X-inactivation analysis. This marker has recently been used to confirm germ line mosaicism in a WiskottAldrich syndrome pedigree which failed to segregate with closely linked loci in the Xpl 1-q22 region.36 Other groups have encountered technical problems and inconsistent results using this marker, however, and these require resolution before its full potential in such studies can be fulfilled.
Advances in management Progress in the molecular biology of WiskottAldrich syndrome has been paralleled by developments in clinical management which have made an important impact on morbidity and survival. Specific therapeutic manoeuvres include regular administration of intravenous immunoglobulin which has been shown to reduce the frequency and severity of infective sequelae, and splenectomy for selected patients who are particularly prone to serious internal bleeding. The importance of long term prophylaxis with antibiotics, with or without immunoglobulin replacement, to prevent overwhelming sepsis after splenectomy has been emphasised.'7 The place of HLA-matched allogenic bone marrow transplantation as the treatment of choice is now well established and expert opinion favours early intervention if an appropriate donor is available."8 Although HLA-haploidentical marrow transplants have proved less successful in Wiskott-Aldrich syndrome, mainly because of graft failure, a preliminary study suggests that this might be overcome by more aggressive conditioning regimens.'9 Given the pre-existing susceptibility of patients with Wiskott-Aldrich syndrome to malignancy, however, it is important to determine whether such treatment leads to an unacceptably high risk of secondary tumours. An alternative approach to the problem of graft rejection has recently been advocated by Fischer et al,' who showed that treatment of recipients with anti-LFA-1 antibody improved graft survival and outcome possibly by blockade of T cell-target cell adhesion. Finally, with accelerating developments in the molecular genetics of WiskottAldrich syndrome, localisation of the mutant Wiskott-Aldrich syndrome gene is now a credible objective and retroviral mediated somatic gene transfer might offer a cure in the future.
